✦ LIBER ✦

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients

✍ Scribed by T. Heise; E. U. Graefe-Mody; S. Hüttner; A. Ring; D. Trommeshauser; K. A. Dugi

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term safety, tolerability, and effi

✍ Masato Odawara; Takashi Kadowaki; Naoko Tajima; Mikio Nishii; Tadaaki Taniguchi; 📂 Article 📅 2011 🏛 Springer Japan 🌐 English ⚖ 377 KB

Pharmacokinetics and pharmacodynamics of

✍ Kyoung Soo Lim; Joo-Youn Cho; Bo-Hyung Kim; Jung-Ryul Kim; Hwa-Sook Kim; Dong-Ky 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 762 KB

Glucose-lowering activity of the dipepti

✍ J. Rosenstock; S. Sankoh; J. F. List 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 413 KB

Efficacy and safety of the dipeptidyl pe

✍ I. Raz; M. Hanefeld; L. Xu; C. Caria; D. Williams-Herman; H. Khatami; Sitaglipti 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 160 KB

The oral DPP-4 inhibitor linagliptin sig

✍ T. Forst; B. Uhlig-Laske; A. Ring; A. Ritzhaupt; U. Graefe-Mody; K. A. Dugi 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 578 KB

Effect of sitagliptin, a dipeptidyl pept

✍ L. Xu; C. Dalla Man; B. Charbonnel; G. Meninger; M. J. Davies; D. Williams-Herma 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB